Treponema Pallidum TP17 (E.col

Recombinant Treponema Pallidum TP17 (N-6His-Sumo)

 

Catalog #:  DRA94       Derived From: E.coli  

 

Description: 

Recombinant Treponema Pallidum TP17 is produced by our E.coli expression system and the target gene encoding Cys22-Lys156 is expressed with a 6His, Sumo tag at the N-terminus.

Accession:  P29722

Names(Known as): 17 kDa lipoprotein; tpp17; TP_0435; TP17; TP0435; Treponema Pallidum TP17

 

Quality Control:

Mol Mass: 28.1kDa      AP Mol Mass:  32kDa, reducing conditions

Purity: Greater than 95% as determined by reducing SDS-PAGE.

 

Formulation:

Supplied as a 0.2 μm filtered solution of 50mM Tris-HCl, 10mM GSH, pH8.0

 

Shipping:

The product is shipped on dry ice pack.

Upon receipt, store it immediately at the temperature listed below.

 

Storage:

Reconstituted protein solution should be stored at  ≤ -20°C.

 

Purification: 

Affinity purification chromatography.

 

Application:

Immunogen, calibrator or standard.

 

Background:

Syphilis remains a prominent sexually transmitted infection worldwide. It is caused by the bacterial spirochete Treponema pallidum, which is an obligate human pathogen. TP17 (also known as TP0435) has some sequence homology (20% identity) to NlpE. In E. coli, this latter protein is anchored to the outer membrane and can activate the Cpx cell envelope stress response pathway. In T. pallidum, however, it is likely that TP17 does not have this function, inasmuch as the genome of this organism apparently does not encode other members of the Cpx pathway; also, TP17 is likely localized to the periplasm.

 

Reference:

Multi-Epitope Vaccine Design Using an Immunoinformatic Approach for SARS-CoV-2[J]. Ye Feng. et al. Pathogens. 2021.

 

 

 

FOR RESEARCH OR FURTHER MANUFACTURING USE ONLY